News
09.12.22

Dr. Robert F. Melendez, One of the Highest Volume Ophthalmic Surgeons in the Country, Joins Ocular Science Medical Advisory Board

SoCal biotech’s leadership team expands to more than 30 ophthalmology and optometry key opinion leaders across the U.S.

EL SEGUNDO, Calif. (September 12, 2022) – Dr. Robert F. Melendez, MD, MBA, CEO/Founder of the Juliette Eye Institute in Albuquerque, N.M., is the newest addition to the Ocular Science® medical advisory board (MAB). Dr. Melendez, who is also a clinical professor at the University of New Mexico Health Sciences Center and medical correspondent at the ABC-TV affiliate in Albuquerque, is joining a board that establishes strategies that focus on enhanced clinical solutions, products and outcomes for Ocular Science and affiliated 503A compounding pharmacy OSRX®

Dr. Melendez, who has performed more than 15,000 cataract and refractive surgeries and was the first in Albuquerque to offer Laser Cataract Surgery (LenSx®) and SMILE, started his own business magazine (Ophthalmology Business Minute) and served in the U.S. Air Force as a fight surgeon before separating from the military as a Lieutenant Colonel.

“My practice is predicated on the philosophy that the company behind the product must deliver exemplary customer service,” says Dr. Melendez, who began using compounded ophthalmic medications when he opened the Juliette Eye Institute in 2020.  “I was initially a slow adopter of compounded drugs, but I quickly learned it allows me to personalize care for every one of my patients. The Ocular Science and OSRX teams understand people and customers better than anybody else in the industry. I am eager to lend my insights and expertise to the Ocular Science medical advisory board, a collection of sharp medical leaders who are partnering to improve the patient experience.” 

OSRX is a 503A compounding pharmacy that customizes OMNI by OSRX ophthalmic medications that are patient-specific and have been prescribed for surgical vision correction, myopia and glaucoma management. OSRX combines multiple medications into a single bottle to supply patients with simple-to-use, cost-efficient solutions by minimizing dosing complexity.

“Dr. Melendez has long established himself as a thought-leader in the industry and, more recently, emerged as a leading voice for compounded medications,” says Eric Garner, Ocular Science Chief Commercial Officer. “Combined with his prowess as a surgeon, Dr. Melendez is an abundantly qualified and welcome addition to our medical advisory board – an elite group which has been instrumental in helping us achieve record financial growth year after year.” 

 

ABOUT OCULAR SCIENCE & OSRX

Ocular Science®, headquartered in El Segundo, Calif., was founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company is guided by a medical advisory board of world leaders in ophthalmology and focuses on the production, marketing and sales of compounded ophthalmic products. OSRX® – an affiliate of Ocular Science – is a PCAB-accredited 503A compounding pharmacy located in Missoula, Mont. that prepares customized medications in four areas of ophthalmology.

Professional Disclosure: Dr. Melendez is on the board for directors and a medical advisory board member for Ocular Science® (an OSRX affiliate) and has a financial interest in the company.

OSRX operates in full compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.